Transcode Therapeutics Inc
NASDAQ:RNAZ
Transcode Therapeutics Inc
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company is headquartered in Boston, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2021-04-28. The company has developed a modular, iron oxide nanoparticle-based nanocarrier system for the delivery of RNA therapeutics to tumors. The Company’s lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include two solid tumor programs such as TTX-siPDL1, a small interfering RNA (siRNA)based modulator of programmed death-ligand 1 (PD-L1), and TTX-siLin28b, a siRNA-based inhibitor of RNA-binding protein LIN28B.
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company is headquartered in Boston, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2021-04-28. The company has developed a modular, iron oxide nanoparticle-based nanocarrier system for the delivery of RNA therapeutics to tumors. The Company’s lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include two solid tumor programs such as TTX-siPDL1, a small interfering RNA (siRNA)based modulator of programmed death-ligand 1 (PD-L1), and TTX-siLin28b, a siRNA-based inhibitor of RNA-binding protein LIN28B.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
